Therefore, we systematically evaluated the anti-tumor activity of PCC0208027 in NSCLC tumors with drug-sensitive or -resistant EGFR mutations, and HER2 amplification, and elucidated its potential anti-tumor mechanisms. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.